News for Agent

Daily business news: funding, M&A, launches

Research & Clinical Trials

Johnson & Johnson TREMFYA Meets Phase 4 STAR Endpoints in Axial Psoriatic Arthritis

By ·

Key takeaways

  • TREMFYA reduced SPARCC MRI sacroiliac joint inflammation scores by -7.1 (Q4W) and -5.2 (Q8W) versus -2.4 for placebo at Week 24.
  • BASDAI scores improved by -3.3 with TREMFYA every four weeks and -2.9 every eight weeks versus -2.1 with placebo.
  • The Phase 4 STAR study enrolled 411 participants worldwide and is the first dedicated randomized, double-blind, placebo-controlled trial of an IL-23 inhibitor in MRI-confirmed axial PsA.

Johnson & Johnson said on November 20, 2026 that its Phase 4 STAR study of TREMFYA (guselkumab) met primary and major secondary endpoints in biologic-naïve adults with active psoriatic arthritis and axial involvement, with MRI-assessed sacroiliac joint inflammation falling more than twice as much as with placebo at Week 24. The PR Newswire release carried the late-breaking results, presented at the Emirates Society for Rheumatology Annual Meeting.

Inside the STAR Trial Results

Johnson & Johnson Services, Inc. is the New Brunswick-based pharmaceutical and medical-technology group behind TREMFYA, a dual-acting monoclonal antibody that blocks IL-23 and binds to CD64. STAR is a Phase 4, multicenter, randomized, double-blind, placebo-controlled study that enrolled 411 participants worldwide, with a 24-week placebo-controlled period followed by 24 weeks of active treatment.

On the 10-point BASDAI scale, mean scores improved by -3.3 with TREMFYA 100 mg every four weeks and -2.9 every eight weeks, against -2.1 for placebo at Week 24. ASDAS-CRP fell by -1.5 and -1.3 respectively versus -0.8, exceeding the ≥1.1-unit threshold for clinically important improvement. On the SPARCC MRI score, TREMFYA reduced sacroiliac joint inflammation by -7.1 and -5.2 versus -2.4 for placebo.

"In the STAR study, TREMFYA showed significant improvements in patient-reported symptoms and MRI-assessed axial inflammation in the sacroiliac joints, backed by a well-characterized safety profile," said Prof. Mikkel Ostergaard of the University of Copenhagen and Rigshospitalet. David M. Lee, Johnson & Johnson's Global Immunology Therapeutic Area Head, said the study "uniquely" establishes evidence for an IL-23 inhibitor in axial PsA. The company said the overall safety profile was consistent with TREMFYA's established profile in psoriatic disease, with no new safety signals.

Johnson & Johnson's Deal Record

According to akta.pro company records, Johnson & Johnson completed the $14.6 billion acquisition of Intra-Cellular Therapies in January 2025, expanding its neuroscience and CNS pipeline. The same records show the company acquired Halda Therapeutics for $3.05 billion in November 2025, adding RIPTAC therapies and the HLD-0915 candidate targeting metastatic castration-resistant prostate cancer.

Earlier Research and Regulatory Steps

On November 19, 2026, The Motley Fool reported that Johnson & Johnson's JNJ-6143 showed a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer at ESMO 2026. The same day, PR Newswire reported that Johnson & Johnson submitted a supplemental NDA to the FDA for CAPLYTA to treat manic or mixed episodes in bipolar I disorder, supported by two Phase 3 studies showing significant symptom reduction versus placebo as early as Day 3.

What Comes Next for TREMFYA

The STAR results are scheduled for presentation at the Emirates Society for Rheumatology Annual Meeting in Dubai, United Arab Emirates, running November 20-22, 2026. TREMFYA is not approved for every-four-weeks dosing in the U.S., and the company's release lists no filing date for an axial PsA label update.

Companies in this story

Sources

Machine-readable: Markdown · JSON